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Abstract
It has been suggested that the measurement of metronidazole clear-
ance is a sensitive method for evaluating liver function. The aim of this
study was to evaluate the usefulness of plasma hydroxy-metronida-
zole/metronidazole ratios as indicators of dynamic liver function to
detect changes resulting from the various forms of chronic hepatitis C
virus (HCV) infection. A total of 139 individuals were studied: 14
healthy volunteers, 22 healthy, asymptomatic, consecutive anti-HCV-
positive HCV-RNA negative subjects, 81 patients with chronic hepa-
titis C (49 with moderate/severe chronic hepatitis and 34 with mild
hepatitis), and 20 patients with cirrhosis of the liver. HCV status was
determined by the polymerase chain reaction. Plasma concentrations
of metronidazole and its hydroxy-metabolite were measured by re-
verse-phase high-performance liquid chromatography with ultraviolet
detection in a blood sample collected 10 min after the end of a
metronidazole infusion. Anti-HCV-positive HCV-RNA-negative in-
dividuals demonstrated a significantly reduced capacity to metabolize
intravenously infused metronidazole compared to healthy individuals
(0.0478 ± 0.0044 vs 0.0742 ± 0.0232). Liver cirrhosis patients also had
a reduced plasma hydroxy-metronidazole/metronidazole ratio when
compared to the other groups of anti-HCV-positive individuals (0.0300
± 0.0032 vs 0.0438 ± 0.0027 (moderate/severe chronic hepatitis) vs
0.0455 ± 0.0026 (mild chronic hepatitis) and vs 0.0478 ± 0.0044 (anti-
HCV-positive, HCV-RNA-negative individuals)). These results sug-
gest an impairment of the metronidazole metabolizing system induced
by HCV infection that lasts after viral clearance. In those patients with
chronic hepatitis C, this impairment is paralleled by progression of the
disease to liver cirrhosis.
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Introduction
Hepatitis C virus (HCV) is a blood-borne
pathogen apparently endemic in most parts
of the world (1), and, therefore a major
public health problem (2). HVC infection is
a frequent cause of chronic liver disease,
progressing in the majority of patients to
persistent viremia and chronic hepatitis (3-
5). Mortality associated with chronic hepati-
tis C results mainly from liver cirrhosis and
complications such as liver carcinoma (6).
The common course of chronic hepatitis C
involves slow progression. However, the
spectrum of liver disease is broad and pro-
gression rates are extremely variable (5,7).
The long-term outcome is difficult to predict
since patients with chronic hepatitis are sel-
dom symptomatic and end-stage liver dis-
ease, when it occurs, can take more than
three decades to develop (8).
Physical evaluation, the measurement of
biochemical parameters, imaging procedures
(such as ultrasound or computed tomogra-
phy) and liver biopsy are used routinely to
evaluate chronic HCV carriers and to deter-
mine the degree and extension of liver injury
and the prognosis of the disease. However,
the extent to which these variables estimate
hepatic reserve is controversial. Parameters
such as albumin and coagulation factors may
also be used, but they lack sensitivity and
occur late in the course of chronic liver
disease (9,10). Thus, a test that could dis-
criminate more subtle impairments of he-
patic function would be extremely useful.
Dynamic liver function tests such as in-
docyanine green clearance (11), caffeine
elimination (12) and lidocaine metabolism
(13) have been used to complement standard
liver assessment in patients with liver dis-
ease. Metronidazole clearance has been re-
cently proposed as a highly sensitive method
for evaluating liver function (14). This
method consists of measuring plasma hy-
droxy-metronidazole/metronidazole ratio by
high-performance liquid chromatography
(HPLC) following the intravenous adminis-
tration of a single dose of metronidazole.
The test has been used to show that anti-
HCV-positive blood donors and chronic
hepatitis C patients have a decreased capac-
ity to metabolize metronidazole compared to
healthy individuals, thus demonstrating its
usefulness for detecting impaired liver func-
tion in HCV-infected individuals, even in
the absence of liver cirrhosis (14). These
findings suggest that the evaluation of met-
ronidazole metabolism may provide an easy-
to-perform, dynamic liver function test. The
present study was conducted in order to
determine whether the hydroxy-metronida-
zole/metronidazole test could discriminate
between different stages of  hepatic func-
tional impairment during the various stages
of chronic HCV infection as well as the
impact of viral load and genotype on metro-
nidazole metabolism.
Material, Subjects and Methods
Material
Metronidazole and tinidazole were pur-
chased from Sigma (St. Louis, MO, USA).
Hydroxy-metronidazole was synthesized at
Unidade Integrada de Farmacologia e Gas-
troenterologia, Universidade São Francisco,
Bragança Paulista, SP, Brazil. Analytical
grade potassium, dihydrogen phosphate, so-
dium hydroxide, phosphoric acid, and HPLC-
grade methanol were obtained from Merck
S.A. Indústrias Químicas (Rio de Janeiro,
RJ, Brazil). Analytical grade zinc sulfate and
tetrahydrofuran were purchased from Reagen
(Rio de Janeiro, RJ, Brazil) and Riedel de
Haen AG (Seelze, Germany), respectively.
Subjects
Five groups of subjects were studied:
healthy volunteers (N = 14), anti-HCV-posi-
tive HCV-RNA-negative individuals (N =
22), asymptomatic HCV-RNA-positive pa-439
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tients (N = 34), patients with HCV-associ-
ated chronic hepatitis (N = 49), and patients
with HCV-associated liver cirrhosis and pre-
served liver function (N = 20). All patients
with circulating HCV-RNA were submitted
to a percutaneous liver biopsy, unless con-
traindicated.
Patients with abnormal bilirubin, albu-
min, prothrombin time, ascites, and encepha-
lopathy and/or those diagnosed with liver
tumors were excluded from the study. Indi-
viduals using drugs which could influence
cytochrome P450 function were also ex-
cluded.
The clinical protocol was approved by
the São Francisco University Ethics Com-
mittee, and the study was conducted in ac-
cordance with the Declaration of Helsinki.
All individuals gave written informed con-
sent prior to entering the study.
Volunteer selection
Healthy volunteers were enrolled follow-
ing assessment of their medical history, nor-
mal physical examination and laboratory
tests, including negative serology for hepati-
tis B and C and the absence of alcoholism. A
total of 139 individuals were included in the
study: 14 healthy volunteers (males = 11,
median age = 32 years, range 19-48 years),
22 healthy, asymptomatic, consecutive anti-
HCV-positive HCV-RNA-negative individu-
als (males = 14, median age = 37 years, range
20-63 years), 81 anti-HCV-positive HCV-
RNA-positive individuals (males = 61, me-
dian age = 36 years, range 22-62 years), and
20 liver cirrhosis patients (males = 13, me-
dian age 44, range 29-44 years). Genotype 1
was the most prevalent. Forty-nine patients
with circulating HCV-RNA had moderate/
severe chronic hepatitis (males = 37, median
age 38 years, range 23-57 years), and 34
subjects had mild hepatitis (males = 24,
median age 35 years, range 22-62 years)
according to the criteria of Desmet et al.
(15).
Anti-HCV-positive HCV-RNA-negative
individuals
Asymptomatic, healthy consecutive anti-
HCV-positive HCV-RNA-negative individu-
als, without previous treatment for HCV in-
fection, were tested for anti-HCV antibodies
using an enzyme immunoassay (Abbott HCV
EIA, 2nd generation, Abbott Laboratories
Diagnostics Division, Chicago, IL, USA).
All positive results were confirmed using a
gelatin particle agglutination test with re-
combinant antigens C22-3 and C200
(Serodia-HCV, Fujirebio Inc., Tokyo, Ja-
pan). Anti-HCV-positive individuals were
considered to have cleared HCV if serum
levels of enzymes synthesized by the liver
such as alanine aminotransferase (ALT), as-
partate aminotransferase (AST), alkaline
phosphatase, and gamma-glutamyl transpep-
tidase were within the normal reference
range, and if no circulating HCV-RNA could
be detected by the polymerase chain reaction
(PCR). Each patient was tested on three
different occasions with at least one month
between tests.
Non-cirrhotic hepatopathy
Anti-HCV-positive HCV-RNA individu-
als had anti-HCV-positive serum (as meas-
ured by EIA, circulating HCV-RNA and per-
sistently abnormal liver enzymes, but no
other forms of viral hepatitis (negative serol-
ogy for HBV). The absence of liver cirrhosis
was assessed by clinical evaluation, ultra-
sonography and/or a CT scan, and was con-
firmed by a liver biopsy.
HCV-associated liver cirrhosis
Liver cirrhosis patients were selected for
the study based on their medical history,
clinical signs and the presence of diffuse
alterations in the liver parenchyma detected
by ultrasonography or a CT scan. When
possible, the diagnosis of cirrhosis was con-440
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firmed by a liver biopsy. The patients in-
cluded were classified as A according to the
Child-Pugh scale (11). Patients with liver
tumors, an ongoing bacterial infection, or
renal failure (as determined by serial serum
creatinine determinations) were excluded
from the study. The presence of an ongoing
bacterial infection was assessed by clinical
evaluation, chest radiology and urine analy-
sis.
Clinical laboratory analysis
Serum chemical analysis,  urinalysis, a
complete blood cell and platelet count, pro-
thrombin, albumin, serum AST, ALT, alka-
line phosphatase, γ-glutamyl transpeptidase,
total bilirubin, prothrombin time, hemato-
crit, and total/differential white cell counts
were determined in all subjects.
Histology
Biopsy specimens were fixed in 10%
formalin. Sections, 3 to 4 µm thick, were cut
and stained with hematoxylin-eosin and
Masson trichrome or silver for reticulin fi-
bers. For each biopsy specimen, necro-in-
flammation was graded and the stage of
fibrosis was classified according to Desmet
et al. (15). The sum of the necro-inflamma-
tory and fibrosis score was considered to be
the final score and used to define mild and
moderate/severe chronic hepatitis. Chronic
hepatitis is defined as mild if the final score
was 5 or less and moderate or severe if >5.
Plasma hydroxy-metronidazole/metronidazole
ratio
The study consisted of a single intrave-
nous administration of metronidazole  (Flagyl®,
5 mg/ml, Rhodia, São Paulo, SP, Brazil) for
20 min. At the end of the infusion, the can-
nula was washed with 20 ml sterile saline. A
blood sample (5 ml) was collected from an
antecubital vein into EDTA-containing tubes
before and 10 min after the infusion. Blood
samples were centrifuged at 2,000 g for 5
min and plasma was stored at -20ºC until
assayed. The participants remained in the
Clinical Pharmacology Unit during metroni-
dazole administration and blood sampling.
Plasma metronidazole concentration
The plasma concentrations of metronida-
zole and its hydroxy-metabolite were meas-
ured by a validated reversed-phase HPLC
method (14). The separation was performed
on a reversed-phase Luna C18 column (250
x 4.6 mm ID, 10 µm; Phenomenex, Tor-
rance, CA, USA) protected by a Security-
guard C18 guard column (4.0 x 3.0 mm;
Phenomenex). The mobile phase consisted
of 85% methanol and 15% 0.01 M potas-
sium dihydrogen phosphate buffer adjusted
to pH 4.5 and was eluted at a flow rate of 1.8
ml/min. The detector wavelength was set at
324 nm and peak heights were measured.
For the extraction, 50 µl of the internal stan-
dard (tinidazole, 100 µl in methanol) was
added to 200 µl of plasma. After mixing,
deproteinization was carried out by adding
20 µl 0.6 M ZnSO4 and 20 µl 0.4 M NaOH.
The samples were vortex mixed and the
tubes were then centrifuged at 2000 g for 5
min. Twenty microliters of each supernatant
was injected into the HPLC system. The
plasma hydroxy-metabolite/metronidazole
ratios were determined in all participants.
This method has a sensitivity of 100 ng/ml
and the mean intra-assay coefficient of varia-
tion (up to 25 µg/ml of both compounds) is
4%.
HCV-RNA detection, quantification and
genotyping
HCV-RNA was extracted from 140 µl of
serum with RNA viral QiaAMP (Qiagen,
Valencia, CA, USA), reverse transcribed
(RT)-PCR and amplified by nested PCR us-
ing 5’NCR specific primers 939, 209, 940,441
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and 211 as previously described (16). Using
the enzymes RsaI-HaeIII and BstNI-HinfI,
followed by digestion with ScrFI or BstUI,
we were able to identify and distinguish the
HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5,
and 6.
Viral load was evaluated by means of
real-time quantitative RT-PCR, as previously
described (17-19). The use of a sequence
detector (ABI Prism 7700; Applied Biosys-
tems, Foster City, CA, USA) allows meas-
urement of the amplified product in direct
proportion to the increase in fluorescence
emission continuously during PCR amplifi-
cation. A value above or below 800,000 IU/
ml was used to define a high or low viral load
(20).
Statistical analysis
Data are reported as means ± SEM unless
otherwise stated. All variables were ana-
lyzed by one-way ANOVA followed by the
Student t -test for multiple comparisons
among groups, with the level of significance
set at P < 0.001.
Results and Discussion
The data in Table 1 show that the plasma
hydroxy-metronidazole/metronidazole ratio
revealed a reduced capacity of HCV-infected
individuals to metabolize intravenously in-
fused metronidazole compared to healthy
individuals, regardless of their HCV-RNA
status, as indicated by the lower ratio com-
pared to volunteers. Liver cirrhosis patients
also had a reduced plasma hydroxy-metroni-
dazole/metronidazole ratio when compared
to the other groups of anti HCV-positive
individuals (Table 1). The HCV genotype
was not related to differences in the plasma
hydroxy-metronidazole/metronidazole ratios
among patients with chronic hepatitis (Table
2). Similar data for viral load were found
(0.0443 ± 0.017 vs 0.0449 ± 0.0163 for low
and high viral load, respectively; 95% CI:
Table 1.         Plasma hydroxy-metronidazole/metronidazole ratios 10 min after intravenous
administration of 500 mg metronidazole in patients with hepatitis C virus-induced liver
disease.
Group OH-MET/MET ratio
Healthy volunteers (N = 14) 0.0742 ± 0.0232
Anti-HCV-positive HCV-RNA-negative 0.0478 ± 0.0207*+
individuals (N = 22) (0.0115;0.0414)a
(0.0072;0.0029)b
Mild chronic hepatitis (N = 34) 0.0455 ± 0.0152*+
(0.0154;0.0419)a
(0.0075;0.0237)b
Moderate/severe chronic hepatitis (N = 43) 0.0438 ± 0.0187*+
(0.0183;0.0445)a
(0.0050;0.0207)b
Liver cirrhosis (N = 20) 0.0300 ± 0.0143*
(0.0306;0.0579)a
(0.0072;0.0285)c
Data are reported as means ± SEM. The numbers in parentheses indicate the upper
and lower limits of the 95% confidence intervals of the significant differences com-
pared to ahealthy volunteers, bpatients with liver cirrhosis and canti-HCV + RNA
individuals. OH-MET/MET ratio = hydroxy-metronidazole/metronidazole ratio.
*P < 0.001 vs healthy volunteers, +P < 0.001 vs patients with liver cirrhosis (one-way
ANOVA followed by the Student t-test).
-0.0080; 0.0070). Therefore, only two groups
of patients were formed: individuals with
mild hepatic histological alterations and in-
dividuals with moderate/severe hepatitis.
Chronic viral hepatitis is a silently pro-
gressive disease with a heterogeneous course,
Table 2. Plasma hydroxy-metronidazole/metronidazole ratios according to genotype
and histological score.
OH-MET/MET ratio
G1 G3
Chronic mild hepatitis 0.0479 ± 0.0157 0.0418 ± 0.0147
G1 (N = 21) (-0.0043;0.0165)
G3 (N = 13)
Chronic moderate/severe hepatitis 0.0407 ± 0.0198 0.0477 ± 0.0139
G1 (N = 24) (-0.0170;0.0031)
G3 (N = 19)
See legend to Table 1 for a description of the ratios. Data are reported as means ±
SEM. The numbers in parentheses indicate the upper and lower limits of the 95%
confidence intervals of the significant differences compared to G3. OH-MET/MET
ratio = hydroxy-metronidazole/metronidazole ratio; G1 = genotype 1; G3 = genotype
3. There were no significant differences between G1 and G3 (one-way ANOVA
followed by the Student t-test).442
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making the clinical outcome difficult to pre-
dict (7). Since standard liver tests are not
useful for predicting the progress of fibrosis
in chronic hepatitis patients, a truly quantita-
tive test for liver function could allow a
prognostic assessment of various liver dis-
eases (21).
A reliable quantitative liver test would be
useful for clinicians and researchers when
deciding on therapeutic strategies. The search
for such a test has been going on for many
years and is complicated by the lack of a
universally accepted standard. The forma-
tion of monoethylglycinexylidide (MEGX),
the main lidocaine metabolite, has been sug-
gested as a simple and valuable liver func-
tion test (22-24). However, the administra-
tion of lidocaine may produce side effects in
a high percentage of individuals tested (22),
the formation of MEGX may be influenced
by age and gender (24,25), and the lidocaine
dose to be administered and the time point
for measuring the MEGX concentration are
still controversial (26-28). The MEGX test
has also failed to discriminate between
healthy volunteers and patients with chronic
hepatitis (10,29).
The present results demonstrate the ability
of the hydroxy-metronidazole/metronidazole
ratio to discriminate between healthy indi-
viduals and patients with Child-Pugh class A
liver cirrhosis, chronic C hepatitis, or even
those with a past HCV infection (Table 2).
Regarding the potential usefulness of the
hydroxy-metronidazole/metronidazole ratio
in early HCV chronic liver disease, we have
shown that this test can discriminate be-
tween Child-Pugh class A liver cirrhosis and
chronic hepatitis C or anti-HCV-positive and
RNA-negative individuals, but not between
the latter patient group and those with chronic
hepatitis C, regardless of the severity of the
disease (Table 2). These results suggest that
HCV infection, regardless of viral load or
genotype, causes abnormalities in liver func-
tion, even though viral clearance may have
already occurred, and that these abnormali-
ties progress with further progression of liver
disease.
Several viral and bacterial infections or
interferon-inducing agents have been asso-
ciated with impaired cytochrome P450-me-
diated drug metabolism. This effect may be
partly mediated by the release of cytokines
or related to autoimmune-mediated phenom-
ena which might be triggered by HCV (30-
37). This immunological imbalance could
lead to interference with drug metabolizing
systems during the acute phase of hepatitis C
and may persist, even when the infection is
self-limited.
Our results indicate an impairment of the
metronidazole-metabolizing system induced
during the acute phase of HCV infection.
This impairment may continue after viral
clearance. In those patients with chronic C
hepatitis, this impairment is paralleled by
progression of the disease to liver cirrhosis,
indicating that the mechanism of damage is
still active and progressive. The hydroxy-
metronidazole/metronidazole ratio was sen-
sitive enough to discriminate among normal
individuals and those with a past or an ongo-
ing HCV infection, confirming our previous
report (14), but could not discriminate those
individuals with a history of HCV infection
from those harboring a chronic hepatitis and
thus, at risk for a progressive liver disease.
Therefore, the usefulness of this test in the
clinical setting needs to be further evaluated.443
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